Are Peptides FDA-Approved?
Some peptides are FDA-approved drugs. Most research peptides are not. This guide explains the difference, which compounds have approval, what the 2023 compounding guidance changed, and what "not approved" actually means.
The Short Answer
Some peptides are FDA-approved; most research peptides are not. FDA-approved peptide drugs include insulin, semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and tesamorelin. Research peptides such as BPC-157, TB-500, CJC-1295, and Ipamorelin are not FDA-approved for any indication. They are sold for laboratory research use only and have not completed the clinical trial process required for drug approval.
FDA-Approved Peptide Drugs
These peptides have completed the full FDA approval process — preclinical studies, Phase I/II/III clinical trials, and NDA/BLA review. They are legally available as prescription drugs for their approved indications.
| Peptide | FDA Approval | Indication | Brand Name(s) |
|---|---|---|---|
| Insulin | 1982 (recombinant) | Type 1 & 2 diabetes | Humulin, Novolog, Lantus |
| Semaglutide | 2017 (Ozempic), 2021 (Wegovy) | Type 2 diabetes / obesity | Ozempic, Wegovy, Rybelsus |
| Tirzepatide | 2022 (Mounjaro), 2023 (Zepbound) | Type 2 diabetes / obesity | Mounjaro, Zepbound |
| Tesamorelin | 2010 | HIV-associated lipodystrophy | Egrifta |
| Bremelanotide | 2019 | Hypoactive sexual desire disorder (HSDD) | Vyleesi |
| Sermorelin | 1997 (withdrawn 2008) | GH deficiency in children | Geref (discontinued) |
| Oxytocin | 1962 | Labor induction, postpartum hemorrhage | Pitocin |
| Vasopressin | Various | Diabetes insipidus, vasodilatory shock | Vasostrict, DDAVP |
| Liraglutide | 2010 (Victoza), 2014 (Saxenda) | Type 2 diabetes / obesity | Victoza, Saxenda |
| Exenatide | 2005 | Type 2 diabetes | Byetta, Bydureon |
Research Peptides: Not FDA-Approved
These are the most commonly researched peptides. None have received FDA approval for human use. They are legal to purchase and use for laboratory research in the United States, but they cannot be legally sold for human consumption or prescribed as drugs (with limited compounding exceptions).
No IND (Investigational New Drug) application filed. Placed on FDA 503A/503B compounding restriction list in 2023.
Thymosin Beta-4 has been studied in wound healing trials but has not received FDA approval. On 2023 compounding restriction list.
GHRH analogue studied in Phase I/II trials. Not submitted for NDA. Research use only.
GHRP studied in Phase I/II trials. Not submitted for NDA. Research use only.
GH secretagogue studied in Phase II trials for muscle wasting. Development discontinued. Not FDA-approved.
Triple agonist (GLP-1/GIP/glucagon). Phase II data published in NEJM 2023. Phase III trials ongoing as of 2026.
FDA issued warning letters to distributors. Not approved for any indication. Sold illegally as 'research chemical.'
Tetrapeptide studied in Russian longevity research. No IND or NDA filed with FDA.
Approved in Russia as an anxiolytic. No FDA IND or NDA. Research use only in the US.
Mitochondria-derived peptide. Early-stage preclinical research. No regulatory submissions.
The FDA Drug Approval Process
Understanding why most research peptides are not FDA-approved requires understanding what approval actually requires. The process takes 10–15 years and costs $1–2 billion on average — which is why many promising research compounds never reach the market.
In vitro and animal studies to establish basic safety and mechanism of action. Can take 3–6 years.
Investigational New Drug application filed with FDA. Required before any human trials can begin.
First-in-human studies. Small cohort (20–100 subjects). Primary focus: safety and dosing.
Larger cohort (100–500 subjects). Establishes efficacy signal and characterizes adverse effects.
Large randomized controlled trials (500–5,000+ subjects). Confirms efficacy and safety at scale.
New Drug Application (or Biologics License Application) submitted to FDA with complete trial data.
FDA review takes 6–12 months (standard) or 6 months (priority review). Advisory committee may convene.
If approved, Phase IV post-market studies monitor long-term safety in the general population.
The 2023 FDA Compounding Guidance
In 2023, the FDA updated its guidance on which bulk drug substances compounding pharmacies (503A and 503B facilities) can use. This was a significant change that affected the availability of several research peptides through medical channels.
Important: The 2023 compounding restrictions affect the human therapeutic market only. They do not change the legal status of these compounds for legitimate laboratory research use. Research peptides remain legal to purchase for research purposes.
| Compound | Compounding Status | Detail |
|---|---|---|
| BPC-157 | Restricted | Added to 503A/503B restriction list. Cannot be compounded for human use by US compounding pharmacies. |
| TB-500 (Thymosin Beta-4) | Restricted | Added to 503A/503B restriction list. Cannot be compounded for human use. |
| Sermorelin | Restricted (2023) | Previously widely compounded. Added to restriction list in 2023 FDA guidance update. |
| CJC-1295 | Restricted | Not on the 503B bulk drug substances list. Cannot be compounded for human use. |
| Ipamorelin | Restricted | Not on the 503B bulk drug substances list. Cannot be compounded for human use. |
| Semaglutide (compounded) | Conditional | Compounded semaglutide was permitted during FDA drug shortage. Shortage status subject to change — check current FDA shortage list. |
What FDA Approval Actually Means
What approval confirms
- Efficacy demonstrated in ≥2 Phase III RCTs
- Safety profile characterized in thousands of subjects
- Manufacturing quality standards (GMP) verified
- Labeling and dosing guidelines established
- Post-market surveillance required
What approval does NOT mean
- The compound is risk-free
- It works for all people equally
- Off-label uses are validated
- Long-term safety is fully known
- It is superior to non-approved alternatives
What 'not approved' means
- Has not completed Phase I/II/III trials
- Safety in humans is not established through RCTs
- Cannot be legally sold for human consumption
- Cannot be prescribed by physicians (with limited exceptions)
- Does not mean it has been tested and found dangerous
Research use distinction
- Legal to purchase for laboratory research
- Not subject to FDA drug approval requirements for research use
- Supplier cannot make therapeutic claims
- Must be labeled 'for research use only'
- Institutional research may require IRB approval
Related Research Guides
Frequently Asked Questions
Are research peptides FDA-approved?
No. Research peptides such as BPC-157, TB-500, CJC-1295, Ipamorelin, and MK-677 are not FDA-approved for any indication. They are sold for laboratory and preclinical research use only. FDA approval requires successful completion of Phase I, II, and III clinical trials and submission of a New Drug Application — a process that takes 10–15 years and costs hundreds of millions of dollars.
Which peptides are FDA-approved?
Several peptide drugs are FDA-approved, including insulin (1982), semaglutide (Ozempic/Wegovy, 2017/2021), tirzepatide (Mounjaro/Zepbound, 2022/2023), tesamorelin (Egrifta, 2010), bremelanotide (Vyleesi, 2019), liraglutide (Victoza/Saxenda, 2010/2014), and exenatide (Byetta, 2005). These compounds have undergone rigorous clinical trials and regulatory review.
What did the FDA's 2023 peptide guidance change?
The FDA's 2023 guidance updated the list of bulk drug substances that compounding pharmacies (503A and 503B facilities) can use. It added BPC-157, TB-500, sermorelin, CJC-1295, and ipamorelin to the restriction list, meaning these compounds can no longer be legally compounded for human use by US pharmacies. This does not affect their legal status for research use — they remain legal to purchase and use for laboratory research.
Does 'not FDA-approved' mean a peptide is dangerous?
Not necessarily. 'Not FDA-approved' means the compound has not completed the clinical trial process required for approval as a human drug — it does not mean it has been tested and found dangerous. Many research peptides simply have not been through the approval process due to cost, lack of commercial interest, or early-stage research status. However, the absence of approval also means their safety and efficacy in humans is not established through the same rigorous process as approved drugs.
Can a doctor prescribe non-FDA-approved peptides?
Physicians can prescribe FDA-approved drugs off-label (for indications other than their approved use). They can also prescribe compounded medications from licensed compounding pharmacies — but only for compounds that are legally compoundable. The 2023 FDA guidance restricted compounding of BPC-157, TB-500, and several GH-axis peptides, significantly limiting physicians' ability to prescribe these compounds legally.
Is semaglutide the same as research-grade GLP-1 peptides?
Semaglutide (Ozempic/Wegovy) is an FDA-approved GLP-1 receptor agonist that has completed extensive clinical trials. Research-grade GLP-1 analogues sold by research suppliers are not the same product — they are not manufactured to pharmaceutical standards, have not been evaluated for human safety, and are not legally intended for human use. The molecular structure may be similar, but the regulatory status, manufacturing standards, and evidence base are fundamentally different.
Source Research Peptides at Purgo Labs
Third-party tested, ≥99% purity, COA with every batch.